TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Eyepoint Pharmaceuticals
EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration

EyePoint received a positive recommendation from its Data Safety Monitoring Committee for ongoing Phase 3 trials of DURAVYU, a potential treatment for wet age-related macular degeneration. The trials remain on track, with topline data expected in mid-2026.

Insights
QBTS.WS   neutral

Mentioned in related articles, but no specific details provided about its performance or prospects


EYPT   positive

Received positive safety recommendation from independent committee, trials progressing as planned, on track for data readout in mid-2026